| INTRODUCTION
Seizures in cats make up 0.5%-3.5% of all referrals to veterinary teaching hospitals. [1] [2] [3] Several anticonvulsant drugs are available for use in cats with daily administration ranging from 1-3 times daily. [4] [5] [6] [7] To achieve greater seizure control, antiseizure medications should be given at the same time every day, often long term. However, repeated oral administration in cats can be challenging for owners resulting in reduced compliance, poor seizure control, and reduced quality of life for both the cat and owner. All these factors can negatively affect the established human animal bond. 5, 8 Transdermal formulations have been utilized to decrease the difficulty associated with oral medication administration in cats. Phenobarbital, in a lipophilic, liposomic cream (Lipoderm, PCCA Pharmacy), was previously reported to achieve therapeutic concentrations after transdermal administration in healthy cats; however, this medication is not suitable for all cats. 5 Some epileptic syndromes are better 
| MATERIALS AND METHODS
This study was designed as a multidose, prospective, clinical trial. Based on the analysis, cats were prescribed 400 mg/mL transdermal LEV-L at a dosage of 60 mg/kg every 8 hours to be applied to the inner pinna for 6 days. This dosage at 3 times the standard oral dose was selected based on a previous transdermal phenobarbital study in which interim analysis suggested a dose escalation of 3 times the standard oral dosage. 5 Owners were instructed to apply the prescribed amount to a gloved finger and to rub the LEV-L into the inner pinna (or to divide the dose over 2 pinnae) until the cream could no longer be visualized on the gloved finger or inner pinna. Owners were asked to keep a compliance log of dosage times and clinical adverse effects noted throughout the study period. On day 7, cats were hospitalized before administration of the morning dose. Although the median time to steady state is less than 1 day, the study was extended over 7 days to allow for adequate drug absorption as well as to provide a longer observation period for detection of adverse clinical effects. 6 A repeat physical and neurologic examination was performed. Blood sampling was performed at time 0 (trough) and at 0.5, 1, 2, 3, and 4 hours after the morning dose. Transdermal LEV was administered immediately after collection of the trough (time 0) serum sample. The cat's LEV-L was applied using a gloved finger to 1 or both pinnae and rubbed into the pinnae until the gel was no longer observed. At each time point, 1.5 mL of blood was collected via peripheral venipuncture. After collection, blood was allowed to clot for a minimum of 10 minutes followed by centrifugation and manual separation and refrigerated until drug quantification. After the final sample collection, cats were returned to their owners. Transdermal administration of LEV was tapered to every 12 hours on days 7 and 8, and once daily on day 9 before discontinuation of the medication to minimize the risk of withdrawal seizures.
Serum LEV concentrations were determined using high-performance liquid chromatography at a commercial laboratory using a technique previously described for and validated in cats.
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| Statistical analysis
Continuous data were analyzed for all cats using descriptive, nonparametric statistics: median and range for trough and observed peak LEV concentrations, and range of LEV concentrations observed at each time point in each cat. Our measure of a successful outcome was steady-state trough serum LEV concentrations greater than 5 μg/mL with tolerable observed adverse effects at estimated peak concentrations. As the purpose of this study was to determine whether serum drug concentrations remained above an acceptable minimum (5 μg/mL), full pharmacokinetic analysis not performed with this limited sampling protocol.
| RESULTS
A loss of up to 10% concentration was found in the 350 mg/mL LEV-L samples, and a loss of up to 5% concentration was found in 400 mg/mL LEV-L samples over the 5-week analysis period. Based on these results, LEV-L was formulated at 400 mg/mL for this clinical trial.
All 6 cats completed the clinical trial. All cats were domestic short- 
| DISCUSSION
The results of this study show that serum LEV concentrations greater than 5 μg/mL can be achieved using transdermal LEV-L at a dosage of 60 mg/kg every 8 hours. The dosage selected for this study was 3 times higher than the dosage recommended for oral immediate release LEV (20 mg/g PO q 8h) 6 based on prior experience with transdermal phenobarbital absorption. With transdermal phenobarbital, the dosage of 3 times the standard dosage was required to obtain serum concentrations within the therapeutic range in healthy cats. 5 Lower dosages were not evaluated in our current study to confirm this finding with LEV.
The stratum corneum is part of the outermost layer of the epidermis. It consists of approximately 40% keratin, 40% water, and the remainder is lipid. The reported thickness is 3-20 μm in cats. 14 Drug absorption is regulated by the stratum corneum; therefore, penetration of this skin layer is the largest hurdle to transdermal drug absorption. Chronic exposure allows for greater emulsification of the stratum corneum and for formation of a drug depot in the subcutis. 15, 16 With repeated dosing, absorption is enhanced and formation of a drug depot allows for continuous, slow, steady release into the circulation. 15, 16 In these situations, the absorption rate is often slower than the elimination rate resulting in flip-flop kinetics, in which absorption is the primary determinant of drug concentrations in circulation. This is likely the case for LEV-L as total body clearance of LEV is relatively high in cats. 6 The median (±SD) time to steady-state after oral intermediate release LEV administration is 14.74 (4.75) hours. 6 However, this study was extended over 7 days to allow adequate absorption through the epidermis and formation of a drug depot, as well as to provide a longer observation period for detection of adverse clinical effects. 6, 15, 16 Similar studies of other transdermal drugs in cats have also used a 1-week administration period. 17 The minimum therapeutic value targeted in this study (5 μg/mL)
is the lower end of a commonly referenced therapeutic range that has been extrapolated from humans for use in veterinary species. 6, 18 Recent studies in humans have suggested a new target peak range of 12-40 μg/mL and a trough range of 6-20 μg/mL for optimum seizure control using LEV monotherapy. 19 Though serum concentrations
were not above 12 μg/mL for all cats in this study, it did exceed 5 μg/mL. This variation can be attributable to differences in absorption or clearance of the drug. A veterinary therapeutic range has not been established for LEV, nor has clinical efficacy been determined for cats or dogs based on any human therapeutic range. It remains unknown if LEV-L is clinically effective at the dosages prescribed in this study, because this study was not designed as an efficacy study.
Levetiracetam results in few dose-dependent adverse clinical effects in cats. 6, 9, 10, [20] [21] [22] These findings are consistent with our results in which 2 of 6 cats (33%) experienced minor adverse effects. Crusting of the pinnae might have been secondary to transdermal drug administration; however, the low-frequency observation of this adverse effect and the low number of cats evaluated in this study make the association inconclusive. Although few adverse effects were noted in this study, a longer clinical observation period involving more cats might identify additional adverse effects.
The cost for transdermal LEV, using the formula presented in this study, was notably more expensive than standard oral tablets or oral supply, as all these can affect drug absorption. 24 Dosage stratification could increase the utility of LEV-L in cats requiring higher dosages for seizure control and help identify if saturation of the drug depot occurred at the dosage evaluated in this study.
| CONCLUSIONS
The results of this study suggest that transdermal administration of LEV to cats resulted in serum drug concentrations above the minimum human therapeutic range and a few adverse effects were identified.
Furthermore, LEV-L maintained concentrations up to 5 weeks at a concentration of 400 mg/mL and is the recommended formulation for use.
Though minimum human therapeutic concentrations were achieved, transdermal LEV-L dosages should be adjusted based on seizure control and adverse clinical effects until a therapeutic range is established for cats.
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